• Clearmind Medicine won a U.S. patent covering compositions and methods using MEAI salts to regulate binge behaviors.
• The USPTO issued Patent No. 12,350,242, titled “Binge Behavior Regulators.”
• Scope includes potential use in binge-related disorders, including alcohol use disorder.
• Clearmind said the grant lifts its portfolio to 32 issued patents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180755PRIMZONEFULLFEED9749190) on June 18, 2026, and is solely responsible for the information contained therein.